MNOV Medicinova Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MNOV

Price (delayed)

$1.34

Market cap

$65.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.23

Enterprise value

$38.79M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 35
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 8

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. ...

Highlights
Medicinova's gross profit has surged by 54% QoQ
The company's revenue rose by 46% QoQ
The quick ratio has contracted by 48% YoY but it has grown by 10% from the previous quarter
MNOV's net income is down by 5% YoY but it is up by 2.3% from the previous quarter
The equity has declined by 21% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.medicinova.com
Peers: LLY ALKS TEVA NVS

Key stats

What are the main financial stats of MNOV

MNOV stock price

How has the Medicinova stock price performed over time
Intraday
1.52%
1 week
-2.19%
1 month
-4.29%
1 year
-6.29%
YTD
2.29%
QTD
-2.19%

Financial performance

How have Medicinova's revenue and profit performed over time
Revenue
$596,641
Gross profit
$47,934
Operating income
-$12.92M
Net income
-$11.72M
Gross margin
8%
Net margin
-1,964.3%
Medicinova's gross profit has surged by 54% QoQ
The company's revenue rose by 46% QoQ
MNOV's operating margin is up by 33% QoQ
The net margin has grown by 33% from the previous quarter

Price vs fundamentals

How does MNOV's price correlate with its fundamentals

Growth

What is Medicinova's growth rate over time

Valuation

What is Medicinova stock price valuation
P/E
N/A
P/B
1.67
P/S
110.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.02
MNOV's EPS is up by 4.2% since the previous quarter
The equity has declined by 21% year-on-year and by 5% since the previous quarter
The P/B is 10% higher than the last 4 quarters average of 1.5 and 3.1% higher than the 5-year quarterly average of 1.6
The stock's P/S is 56% less than its last 4 quarters average of 247.2
The company's revenue rose by 46% QoQ

Efficiency

How efficient is Medicinova business performance
MNOV's ROIC has shrunk by 59% YoY and by 12% QoQ
MNOV's return on sales is up by 33% since the previous quarter
Medicinova's return on equity has decreased by 31% YoY and by 3.8% QoQ
The ROA fell by 28% YoY and by 2.4% QoQ

Dividends

What is MNOV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNOV.

Financial health

How did Medicinova financials performed over time
MNOV's current ratio is down by 49% year-on-year but it is up by 11% since the previous quarter
The quick ratio has contracted by 48% YoY but it has grown by 10% from the previous quarter
The debt is 100% less than the equity
The equity has declined by 21% year-on-year and by 5% since the previous quarter
The debt has contracted by 15% from the previous quarter and by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.